We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
Read MoreHide Full Article
Key Takeaways
Quest Diagnostics raised 2026 revenue and adjusted EPS guidance after a second-quarter beat.
Organic requisition volume rose 13%, while revenue per requisition fell 2.8%, making volume the key driver.
Lower-margin partnerships, Project Nova spending and fuel costs could slow margin expansion.
Quest Diagnostics Incorporated (DGX - Free Report) raised its 2026 revenue and adjusted earnings guidance after second-quarter results topped expectations. The increase reflects faster testing demand across physician, hospital and consumer channels.
The outlook is improving, but the quality of the upside still matters. Investors must weigh durable organic volume growth against acquisition contributions, lower-margin partnerships and higher spending on operational projects.
Quest Lifts Revenue and Earnings Guidance
Quest now expects 2026 revenues of $11.95 billion to $12.05 billion, up from its prior range of $11.78 billion to $11.90 billion. The revised range implies growth of 8.3% to 9.2%.
Adjusted earnings are projected at $11.05-$11.25 per share, compared with the earlier $10.63-$10.83 range. The new midpoint stands above the Zacks Consensus Estimate of $11.11 per share at the time of the report.
Image Source: Zacks Investment Research
DGX Volume Growth Powers the Second-Quarter Beat
Second-quarter Revenues rose 10.2% to $3.04 billion, exceeding the consensus mark by 2.1%.
Total requisition volume climbed 13.1%, while organic requisition volume advanced 13%. Revenue per requisition fell 2.8%, showing that volume, rather than pricing, carried the quarter. Labcorp Holdings Inc. (LH - Free Report) , another major laboratory-services provider, competes with Quest across diagnostics and health-system relationships, keeping service quality and access central to share gains.
Per, the Zacks Consensus Estimate, revenues are pegged at 11.99 billion for 2026.
Image Source: Zacks Investment Research
Quest Partnerships Add Revenue and Mix Pressure
Corewell Health is expected to contribute about $250 million to 2026 revenues. The joint venture expands Quest’s hospital channel, while the acquired Fresenius Medical Care assets broaden its kidney-care testing capabilities.
Those additions improve scale but come with lower margins. DaVita Inc. (DVA - Free Report) , a comprehensive kidney-care provider, operates across the same broader kidney-health ecosystem that Quest is targeting through risk assessment, dialysis-related testing and post-transplant monitoring. Quest’s opportunity is meaningful, but integration discipline will determine how quickly revenue converts into profit.
In the past year, DGX shares have risen 35.2% compared with the industry’s 33.7% growth.
Image Source: Zacks Investment Research
DGX Spending Could Delay Margin Payoff
Project Nova spending is expected to increase in the second half of 2026, and management also anticipates about $10 million in fuel-cost pressure for the year. Integration expenses and lower-margin partnership revenue add another layer of near-term dilution.
Second-quarter adjusted operating margin declined 40 basis points to 16.5%. Management still expects full-year margin expansion, supported by volume growth, Invigorate savings and less dilution from Corewell and Fresenius later in the year. That outcome depends on cost execution keeping pace with demand.
Quest Signals Back the Improved Earnings View
The raised outlook strengthens the earnings case, but the mix of organic growth, acquired revenues and spending remains important. Sustained requisition gains and productivity savings would make the upgrade more durable, while integration or cost slippage could limit margin expansion.
Quest currently carries a Zacks Rank #2 (Buy), which reflects favorable earnings estimate revision trends over the near term. The stock also has a Momentum Score of A and a VGM Score of A, while its Value Score and Growth Score are both B. The combination points to favorable momentum and balanced style characteristics, though the stock’s premium valuation and execution demands still warrant attention.
View the Zacks #1 Rank List
Image: Bigstock
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
Key Takeaways
Quest Diagnostics Incorporated (DGX - Free Report) raised its 2026 revenue and adjusted earnings guidance after second-quarter results topped expectations. The increase reflects faster testing demand across physician, hospital and consumer channels.
The outlook is improving, but the quality of the upside still matters. Investors must weigh durable organic volume growth against acquisition contributions, lower-margin partnerships and higher spending on operational projects.
Quest Lifts Revenue and Earnings Guidance
Quest now expects 2026 revenues of $11.95 billion to $12.05 billion, up from its prior range of $11.78 billion to $11.90 billion. The revised range implies growth of 8.3% to 9.2%.
Adjusted earnings are projected at $11.05-$11.25 per share, compared with the earlier $10.63-$10.83 range. The new midpoint stands above the Zacks Consensus Estimate of $11.11 per share at the time of the report.
Image Source: Zacks Investment Research
DGX Volume Growth Powers the Second-Quarter Beat
Second-quarter Revenues rose 10.2% to $3.04 billion, exceeding the consensus mark by 2.1%.
Total requisition volume climbed 13.1%, while organic requisition volume advanced 13%. Revenue per requisition fell 2.8%, showing that volume, rather than pricing, carried the quarter. Labcorp Holdings Inc. (LH - Free Report) , another major laboratory-services provider, competes with Quest across diagnostics and health-system relationships, keeping service quality and access central to share gains.
Per, the Zacks Consensus Estimate, revenues are pegged at 11.99 billion for 2026.
Image Source: Zacks Investment Research
Quest Partnerships Add Revenue and Mix Pressure
Corewell Health is expected to contribute about $250 million to 2026 revenues. The joint venture expands Quest’s hospital channel, while the acquired Fresenius Medical Care assets broaden its kidney-care testing capabilities.
Those additions improve scale but come with lower margins. DaVita Inc. (DVA - Free Report) , a comprehensive kidney-care provider, operates across the same broader kidney-health ecosystem that Quest is targeting through risk assessment, dialysis-related testing and post-transplant monitoring. Quest’s opportunity is meaningful, but integration discipline will determine how quickly revenue converts into profit.
In the past year, DGX shares have risen 35.2% compared with the industry’s 33.7% growth.
Image Source: Zacks Investment Research
DGX Spending Could Delay Margin Payoff
Project Nova spending is expected to increase in the second half of 2026, and management also anticipates about $10 million in fuel-cost pressure for the year. Integration expenses and lower-margin partnership revenue add another layer of near-term dilution.
Second-quarter adjusted operating margin declined 40 basis points to 16.5%. Management still expects full-year margin expansion, supported by volume growth, Invigorate savings and less dilution from Corewell and Fresenius later in the year. That outcome depends on cost execution keeping pace with demand.
Quest Signals Back the Improved Earnings View
The raised outlook strengthens the earnings case, but the mix of organic growth, acquired revenues and spending remains important. Sustained requisition gains and productivity savings would make the upgrade more durable, while integration or cost slippage could limit margin expansion.
Quest currently carries a Zacks Rank #2 (Buy), which reflects favorable earnings estimate revision trends over the near term. The stock also has a Momentum Score of A and a VGM Score of A, while its Value Score and Growth Score are both B. The combination points to favorable momentum and balanced style characteristics, though the stock’s premium valuation and execution demands still warrant attention.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.